![]() |
|
|
Vol. 28, Issue 12, 1484-1486, December 2000
Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo
Co., Ltd., Tokyo, Japan
To investigate the mechanism for the enhanced glucuronidation of
valproic acid (VPA) by panipenem (PAPM), a carbapenem antibiotic, in
rat liver, we carried out studies to investigate whether PAPM increases
the activity of UDP-glucuronosyltransferase or the level of
hepatic UDP-glucuronic acid (UDPGA) in rats. PAPM had no effect on the
UDP-glucuronosyltransferase activity toward VPA both in vivo and in
vitro. On the other hand, in vivo treatment with PAPM significantly
increased the hepatic UDPGA level by about 1.7-fold (control:
434.5 ± 65.5 nmol/g of liver; PAPM-treated: 755.2 ± 92.3 nmol/g of liver). The in vitro formation of VPA glucuronide increased
proportionally as a function of the UDPGA concentration up to 0.8 mM.
Therefore, the increase in the level of hepatic UDPGA by PAPM is likely
to be one of the causal factors for enhancing VPA glucuronidation in vivo.